Welcome to our dedicated page for Cullinan Therapeutics news (Ticker: CGEM), a resource for investors and traders seeking the latest updates and insights on Cullinan Therapeutics stock.
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a forward-thinking biopharmaceutical company dedicated to establishing new standards of care for patients through innovative cancer and autoimmune therapies. The company specializes in a modality-agnostic approach, targeting key drivers of disease and harnessing the immune system to eradicate diseased cells.
With a highly experienced team of oncology professionals and drug developers, Cullinan boasts a diversified portfolio of clinical-stage assets sourced from both internal and external collaborations. This includes therapies aimed at inhibiting disease drivers or activating the immune system to address various oncology and autoimmune indications.
Recent Achievements:
- CLN-617: A first-in-class cytokine therapy combining IL-2 and IL-12 for intratumoral injection, shown to activate a broad immune response.
- CLN-619: A first-in-class monoclonal antibody for relapsed/refractory multiple myeloma, aimed at restoring immune recognition of tumor cells.
- CLN-978: A novel CD19xCD3 bispecific T cell engager being developed for systemic lupus erythematosus.
- Zipalertinib: An EGFR inhibitor for non-small cell lung cancer, with promising efficacy and a manageable safety profile.
Financially, Cullinan is well-positioned, having announced a $280 million private placement to support ongoing research and development activities. This funding, combined with current assets, is expected to sustain the company's operations into 2028.
For more detailed insights and updates, visit Cullinan’s website or follow them on LinkedIn and Twitter.
Cullinan Oncology, Inc. (Nasdaq: CGEM) announced the presentation of initial clinical data for its drug CLN-619 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2-6. CLN-619 is a novel antibody targeting MICA and MICB, ligands that interact with immune cells to induce anti-tumor responses. The Phase 1 study focuses on evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of CLN-619, both as a standalone treatment and in combination with pembrolizumab, in patients with advanced solid tumors. The clinical data presentation will take place on June 3, 2023, and aims to showcase the therapeutic potential of CLN-619 across various cancer types.
Cullinan Oncology, Inc. (Nasdaq: CGEM) announces its participation in the Stifel 2023 Targeted Oncology Days on April 26, 2023, at 2:30 PM EDT. The event will feature a fireside chat with CEO Nadim Ahmed, focusing on the company's innovative approaches to cancer therapies. A live webcast will be available on the investor relations website.
Cullinan Oncology is a biopharmaceutical firm committed to developing new cancer treatment standards. The company leverages extensive research in immuno-oncology and translational cancer medicine, aiming to create groundbreaking therapies through its diverse pipeline. They seek to activate the immune system or target oncogenic drivers, positioning their assets for potential market leadership in various cancer indications.
Cullinan Oncology (Nasdaq: CGEM) announced that the FDA has cleared its IND application for CLN-617, a fusion protein combining IL-2 and IL-12 for targeted tumor treatment. This innovative therapy aims to enhance efficacy and reduce toxicity by retaining the drug within the tumor microenvironment post-injection. Cullinan will conduct a Phase 1 clinical trial focusing on advanced solid tumors and exploring the combination of CLN-617 with pembrolizumab. This advancement represents Cullinan's commitment to developing diverse cancer therapies, with CLN-617 being their sixth clinical-stage asset.
Cullinan Oncology (Nasdaq: CGEM) announced the presentation of preclinical data for its assets, CLN-619 and CLN-617, at the 2023 AACR Annual Meeting from April 14-17 in Orlando, Florida. CLN-619 is a humanized IgG1 antibody undergoing a Phase 1 trial for advanced solid tumors, with initial data expected mid-2023. CLN-617 is a first-in-class cytokine therapy combining IL-2 and IL-12, for which an Investigational New Drug application has been submitted to the FDA. Presentations will focus on their therapeutic potential and preclinical research outcomes.
Cullinan Oncology, Inc. (Nasdaq: CGEM) reported strong advancements and financial results for 2022, highlighting a net income of $109.2 million compared to a net loss of $67.5 million in 2021. The company expanded its pipeline by licensing U.S. rights to CLN-418, received FDA clearance for CLN-978, and submitted the IND for CLN-617, potentially positioning six clinical-stage programs by year-end 2023. Research and development expenses increased to $91.9 million in 2022, driven by ongoing clinical trials. The cash position stands at $550.1 million, providing runway into 2026 for ongoing development efforts.
Cullinan Oncology (Nasdaq: CGEM), based in Cambridge, announced that President and CEO, Nadim Ahmed, will present at Cowen’s 43rd Annual Health Care Conference on March 6, 2023, at 11:10 AM EST. The presentation will focus on the company's innovative approaches to oncology therapies. A live webcast will be available on the company’s investor relations website.
Investors interested in one-on-one meetings with Cullinan Oncology’s management can contact their Cowen representative. The company is dedicated to transforming cancer care through its diversified pipeline and scientific excellence.
Cullinan Oncology (CGEM) has secured an exclusive license from Harbour BioMed for the U.S. development of CLN-418/HBM7008, a bispecific immune activator currently in Phase 1 clinical trials. The deal includes a $25 million upfront payment to Harbour BioMed, with potential milestone payments totaling up to $563 million, plus tiered royalties on U.S. sales. CLN-418 targets B7H4 and 4-1BB, aiming to enhance cancer treatment efficacy, especially in solid tumors with low expression of PD-L1. Cullinan expects to expand its clinical pipeline to six assets by the end of 2023, positioning itself at the forefront of the bispecific antibody space.
FAQ
What is the current stock price of Cullinan Therapeutics (CGEM)?
What is the market cap of Cullinan Therapeutics (CGEM)?
What does Cullinan Therapeutics, Inc. specialize in?
What is CLN-617?
What is the purpose of the recent $280 million private placement?
What is Zipalertinib?
What are the latest developments regarding CLN-619?
What types of diseases does Cullinan Therapeutics' portfolio address?
What is the strategic focus of Cullinan Therapeutics?
What is CLN-978 and its target indication?
How does Cullinan Therapeutics ensure the development of promising assets?
Where can I find more information about Cullinan Therapeutics?
